Ixekizumab

[키워드] 1:1 acute respiratory distress syndrome administer anticipated antiviral therapy Arbidol ARDS Autoimmune diseases bind blinded Blinding by mouth carried caused change chemokines China Chinese Chinese Clinical Trial Registry Chloroquine clinical Controlled Course COVID-19 Cytokines Data collection discharge dissemination Efficacy element enrolled epidemic of COVID-19 evaluated excluded experiment first stage first stage) focus global public health group Human monoclonal antibody hypodermic injection IL-17A immune response independent inhibit initiated injection intensive care interferon interleukin interleukin-17A Intravenous injection involved Ixekizumab Lopinavir Lopinavir/ritonavir mouth name Nanjing number objective open open trial Open-label organ injury outcome overactivation parallel group participant Patient patients with COVID-19 Prevent Primary outcome pro-inflammatory cytokine pro-inflammatory cytokines protocol pulmonary pulmonary CT random randomisation randomised randomization Randomized randomized patient randomly divided receive recruitment registration number registry reported Research respiratory respiratory distress Respiratory distress syndrome ribavirin Ritonavir Safety Sample size Severe infection severe infections severity South stages Standard status Study protocol subject Taltz Th17 cell Th17 cells therapy treated Treatment Trial Trial registration Trial Registration Number two group two groups university Version website with COVID-19
[DOI] 10.1186/s13063-020-04925-8 PMC 바로가기 [Article Type] Randomized Controlled Trial